SNDX Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics, Inc. has a net margin of -132.36% compared to Syndax Pharmaceuticals, Inc.'s net margin of 7.47%. Syndax Pharmaceuticals, Inc.'s return on equity of -136.36% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

Syndax Pharmaceuticals, Inc. has a consensus price target of $39.31, signalling upside risk potential of 99.43%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 1.49%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Syndax Pharmaceuticals, Inc. has a beta of 0.476, which suggesting that the stock is 52.361% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.

Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals, Inc. quarterly revenues are $45.9M, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Syndax Pharmaceuticals, Inc.'s net income of -$60.7M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 15.24x versus 12.52x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -132.36% compared to Syndax Pharmaceuticals, Inc.'s net margin of 81.15%. Syndax Pharmaceuticals, Inc.'s return on equity of -136.36% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Syndax Pharmaceuticals, Inc. has a consensus price target of $39.31, signalling upside risk potential of 99.43%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $217.70 which suggests that it could grow by 2.55%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Syndax Pharmaceuticals, Inc. has a beta of 0.476, which suggesting that the stock is 52.361% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals, Inc. quarterly revenues are $45.9M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Syndax Pharmaceuticals, Inc.'s net income of -$60.7M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 32.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 15.24x versus 17.39x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -132.36% compared to Syndax Pharmaceuticals, Inc.'s net margin of 16.24%. Syndax Pharmaceuticals, Inc.'s return on equity of -136.36% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Syndax Pharmaceuticals, Inc. has a consensus price target of $39.31, signalling upside risk potential of 99.43%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -32.56%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Syndax Pharmaceuticals, Inc. has a beta of 0.476, which suggesting that the stock is 52.361% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals, Inc. quarterly revenues are $45.9M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Syndax Pharmaceuticals, Inc.'s net income of -$60.7M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 15.24x versus 1.23x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -132.36% compared to Syndax Pharmaceuticals, Inc.'s net margin of -876.34%. Syndax Pharmaceuticals, Inc.'s return on equity of -136.36% beat Verastem, Inc.'s return on equity of -1773.4%.

Syndax Pharmaceuticals, Inc. has a consensus price target of $39.31, signalling upside risk potential of 99.43%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 59.05%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Verastem, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Verastem, Inc..

Syndax Pharmaceuticals, Inc. has a beta of 0.476, which suggesting that the stock is 52.361% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

Syndax Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals, Inc. quarterly revenues are $45.9M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Syndax Pharmaceuticals, Inc.'s net income of -$60.7M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals, Inc. is 15.24x versus 47.01x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.